ICW Investment Advisors LLC Acquires 4,641 Shares of Eli Lilly and Company $LLY

Posted by George Bondi on May 27th, 2026

Eli Lilly and Company logo ICW Investment Advisors LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 459.1% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 5,652 shares of the company’s stock after buying an additional 4,641 shares during the period. Eli Lilly and Company accounts for 2.2% of ICW Investment Advisors LLC’s investment portfolio, making the stock its 4th largest holding. ICW Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $6,074,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. Expressive Wealth LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth approximately $721,000. Steel Grove Capital Advisors LLC lifted its holdings in Eli Lilly and Company by 103.1% during the 4th quarter. Steel Grove Capital Advisors LLC now owns 604 shares of the company’s stock worth $649,000 after buying an additional 19,986 shares in the last quarter. TrustBank acquired a new stake in Eli Lilly and Company during the 4th quarter worth approximately $2,731,000. Roundview Capital LLC lifted its holdings in Eli Lilly and Company by 14.9% during the 4th quarter. Roundview Capital LLC now owns 7,199 shares of the company’s stock worth $7,737,000 after buying an additional 935 shares in the last quarter. Finally, Flputnam Investment Management Co. lifted its holdings in Eli Lilly and Company by 4.6% during the 4th quarter. Flputnam Investment Management Co. now owns 56,285 shares of the company’s stock worth $60,488,000 after buying an additional 2,471 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Eli Lilly announced it will acquire three vaccine developers — Curevo, LimmaTech Biologics, and Vaccine Company — in deals worth up to about $3.8 billion, expanding its infectious-disease and vaccine portfolio beyond diabetes and obesity. Lilly announces three acquisitions to build infectious disease portfolio
Positive Sentiment: Investors also reacted to strong news from Lilly’s experimental gene therapy VERVE-102, which cut LDL cholesterol and PCSK9 sharply in early trial data, reinforcing optimism around the company’s broader growth pipeline. VERVE-102 trial results
Positive Sentiment: Analysts and media coverage continued to highlight Lilly as a long-term winner in obesity and pharma, supported by persistent demand for its weight-loss drugs and upbeat commentary on its growth prospects. Motley Fool article on undervaluation
Neutral Sentiment: Broader market gains and hopes for a diplomatic resolution between the U.S. and Iran helped lift equities overall, providing a supportive backdrop for Lilly alongside the company-specific headlines. Market wrap article
Neutral Sentiment: Some healthcare-sector weakness on the day may have partially offset the company-specific optimism, but it does not appear to be the main driver for LLY. Healthcare sector decline article

Eli Lilly and Company Trading Up 0.2%

Shares of NYSE:LLY opened at $1,066.77 on Wednesday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The company’s 50 day moving average is $946.28 and its two-hundred day moving average is $1,006.64. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The company has a market cap of $1.00 trillion, a PE ratio of 37.90, a P/E/G ratio of 1.16 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the prior year, the firm posted $3.34 EPS. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts predict that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Bank of America increased their target price on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a report on Tuesday. Freedom Capital upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Rothschild & Co Redburn increased their target price on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Barclays increased their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Finally, Argus increased their price objective on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,227.00.

View Our Latest Analysis on LLY

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.